MenQuadfi Infant Label Win Closes Age Gap With Nimenrix, But Pivotal Data Remain Unpublished

Sanofi's MenQuadfi Gains EU Approval for Infant Use

Sanofi announced that the European Commission (EC) has approved an extension of the indication for MenQuadfi (Meningococcal Group A, C, W and Y conjugate vaccine) to include infants from six weeks of age. This approval helps protect against invasive meningococcal disease caused by Neisseria meningitidis serogroups A, C, W, and Y. Previously, MenQuadfi was approved in the EU for individuals aged 12 months and older. Invasive meningococcal disease is a life-threatening bacterial infection with high mortality rates and severe long-term complications, particularly in infants, making broad protection from an early age crucial.

• The expanded indication for MenQuadfi provides healthcare professionals in the EU with an additional option for vaccinating infants from as early as six weeks of age. This aligns with routine infant immunization schedules, offering greater flexibility and aiming to increase vaccine coverage against a rapidly progressing and devastating disease.
• The EU approval is supported by comprehensive data from the MET58 pivotal clinical study, which evaluated MenQuadfi's immunogenicity, safety, and tolerability in infants from six weeks of age. The vaccine benefits from a strong track record, with clinical data from over 6,000 infants studied across 11 countries, demonstrating a safety profile comparable to other licensed MenACWY vaccines.
• Approved dosing regimens include a 2+1 schedule for infants starting vaccination from six weeks (two doses at least two months apart, booster in the second year of life) and a 3+1 schedule for infants at increased risk of serogroup A exposure (three primary doses, one booster from 12 months). MenQuadfi can also be co-administered with other routine pediatric vaccines like DTaP-IPV-HepB-Hib, rotavirus, and PCV10.

Understanding the Vulnerability of Infants to Invasive Meningococcal Disease

Invasive meningococcal disease (IMD) caused by Neisseria meningitidis does not affect all populations equally — certain demographic groups bear a disproportionate burden of disease, driven by age-related immune vulnerability, behavioral risk factors, and underlying medical conditions. Epidemiological data consistently identify infants, young children, and adolescents/young adults as the primary populations at risk, with additional elevation of risk in immunocompromised individuals.

• Infants and young children carry the highest incidence rates. In Spain, hospitalization rates reached 56.2/100,000 in children under 1 year of age, declining dramatically to 1.3/100,000 in children over 5 years. In AP Vojvodina, Serbia, IMD incidence rates peaked at up to 22.9/100,000 among infants under 1 year and 16.0/100,000 among children aged 1–4 years, with children aged 1–4 years comprising the largest share of all IMD cases over the 28-year study period.

• Adolescents and young adults, including university students, represent a significant proportion of IMD cases and characteristically have the highest carriage rates, increasing both their individual IMD risk and the likelihood of transmission to others. In dormitory settings, carriage rates among university freshmen ranged from 11.8% to 14.1% over a 4-week interval, with "visiting to pubs" associated with carriage at both the first (p=0.047) and second cultures (p=0.026), indicating that close social contact is a relevant behavioral risk factor.

• Individuals with complement deficiencies and other immune defects face substantially elevated IMD risk. Persons with terminal complement defects and properdin deficiency have reported IMD incidences up to 10,000-fold higher than in the general population. Persons with asplenia carry an estimated 20–30-fold increased risk, while individuals with other immune defects such as HIV infection or hypogammaglobulinaemia face an estimated no more than 5–10-fold higher risk than background. A case of IMD associated with complement component 7 deficiency further illustrates that IMD can occur in young, otherwise healthy-appearing individuals who harbor unrecognized underlying complement deficiency.

• Mortality risk is not uniformly distributed across age groups. In AP Vojvodina, the highest IMD mortality rate was observed among infants under 1 year (0.59 per 100,000), followed by children aged 1–4 years (0.32 per 100,000), while the highest case fatality rate (CFR) was recorded among individuals aged ≥40 years (21.4%), followed by the 5–9 years age group (17.4%) and infants under 1 year (16.7%). All confirmed fatal cases in that cohort were due to serogroup B.

The knowledge base does not have sufficient information on this aspect regarding demographic data specific to serogroups A, C, W, and Y individually, as the epidemiological breakdowns provided in the literature do not consistently stratify incidence or mortality by these specific serogroups.

The Pivotal MET58 Study Supporting MenQuadfi's Infant Approval

Two pivotal Phase 3 trials evaluated MenACYW-TT (MenQuadfi) for protection against invasive meningococcal disease caused by Neisseria meningitidis serogroups A, C, W, and Y. These trials assessed immunogenicity and safety across distinct pediatric populations, using serum bactericidal antibody assays as the primary immunological measurement tool.

• Toddler trial (NCT03890367) — study design: A modified, double-blind Phase III study enrolling 701 toddlers aged 12–23 months, randomized to receive one dose of MenACYW-TT (n = 230), MCV4-TT/Nimenrix (n = 232), or MenC-TT/NeisVac-C (n = 239). A sequential statistical approach was applied for primary and secondary objectives, with immunogenicity assessed at baseline and 30 days post-vaccination using both human complement serum bactericidal assay (hSBA) and baby rabbit complement serum bactericidal assay (rSBA).

• Toddler trial — primary endpoints: Superiority of MenACYW-TT serogroup C immune response versus MCV4-TT was assessed by hSBA seroprotection rates (defined as titers ≥1:8) and hSBA geometric mean titers (GMTs); superiority versus MenC-TT was assessed by rSBA GMTs. MenACYW-TT demonstrated superior hSBA GMTs (ratio 16.3 [95% CI 12.7–21.0]), superior hSBA seroprotection (difference 10.43% [95% CI 5.68–16.20]), and superior rSBA GMTs versus MenC-TT (ratio 1.32 [95% CI 1.06–1.64]).

• Infant trial (NCT03537508) — study design: A Phase 3 study enrolling healthy infants ≥6 weeks of age in the USA and Puerto Rico, comparing MenACYW-TT against a licensed quadrivalent meningococcal oligosaccharide diphtheria CRM-conjugate vaccine (MenACWY-CRM) administered concomitantly with routine pediatric vaccines in a four-dose series (3 + 1 schedule). The study ran from April 25, 2018, to September 22, 2023.

• Infant trial — co-primary endpoints: The first co-primary endpoint was seroresponse rates 30 days after the fourth dose at 12–15 months of age; the second was the proportion of participants with hSBA antibody titers ≥1:8 against each serogroup 30 days after the third dose at 6 months of age. Non-inferiority was demonstrated for both endpoints, with serogroup-specific seroresponse rates of 79.4%–97.6% for MenACYW-TT and 77.6%–96.4% for MenACWY-CRM after the fourth dose, and rates of 77.9%–99.0% for MenACYW-TT versus 67.7%–92.9% for MenACWY-CRM after the third dose.

• Safety across both trials: The safety profiles of MenACYW-TT, MCV4-TT, and MenC-TT were described as similar in the toddler trial, and MenACYW-TT and MenACWY-CRM were described as "overall well tolerated" with comparable safety profiles in the infant trial. Safety was assessed within 30 days post-vaccination in the toddler trial.

Integrating MenQuadfi into EU Routine Infant Immunization Schedules

For invasive meningococcal disease (IMD) caused by Neisseria meningitidis serogroups A, C, W, and Y, ceftriaxone is recommended as both empiric and definitive treatment. This recommendation is supported by evidence from adult IMD cohorts, where short-duration intravenous beta-lactam therapy — with a median treatment duration of 3 days of benzylpenicillin or ceftriaxone — proved effective regardless of penicillin susceptibility status. Specifically, for N. meningitidis meningitis caused by an isolate with reduced penicillin susceptibility, ceftriaxone is the preferred agent for both empiric initiation and definitive therapy.

Adjunctive corticosteroid therapy, particularly dexamethasone, is recommended as part of initial empiric therapy in suspected bacterial meningitis, with global and regional guidelines (including WHO, IDSA, and NICE) supporting its use when administered before or with antibiotics. In acute bacterial meningitis, corticosteroids have been shown to significantly reduce mortality and neurological sequelae, particularly in pneumococcal disease. However, a meta-analysis of individual patient data from five randomized, double-blind, placebo-controlled trials (2,029 patients) found that adjunctive dexamethasone was not associated with a statistically significant reduction in death (26.5% on dexamethasone vs. 27.2% on placebo; OR 0.97, 95% CI 0.79–1.19), though it did suggest a reduction in hearing loss among survivors (24.1% vs. 29.5%; OR 0.77, 95% CI 0.60–0.99, p=0.04).

For close contacts of confirmed IMD cases, rifampicin prophylaxis is standard practice. A case report from Hungary documented that rifampicin resistance in N. meningitidis — arising from a point mutation in the rpoB gene — may evolve during prophylactic treatment of contacts, underscoring the importance of centralized rifampicin susceptibility testing of N. meningitidis strains within a defined time frame to enable appropriate prophylaxis selection. In patients with underlying immunodeficiency, standard polysaccharide vaccines may be ineffective, and immunization with conjugate vaccine has been proposed in such cases.

MenQuadfi's Early Start: Reshaping Infant Meningococcal Protection

The European Commission's decision to approve MenQuadfi for infants as young as six weeks marks a pivotal moment in the fight against invasive meningococcal disease (IMD). This life-threatening infection, known for its rapid progression and severe long-term consequences, poses a particularly grave threat to infants. Historically, vaccination strategies have faced challenges, with older polysaccharide vaccines lacking the ability to induce immune memory and showing poor immunogenicity in very young children. The advent of conjugate vaccines, like MenQuadfi, has been transformative, and this latest approval extends that protection to the earliest stages of life.

This expanded indication means that healthcare providers in the EU can now offer comprehensive protection against serogroups A, C, W, and Y significantly earlier than before, addressing a critical gap in pediatric immunization schedules. Clinical research has consistently shown MenQuadfi to be safe and immunogenic in infants, even when administered concomitantly with other routine pediatric vaccines, without compromising the immune response to either. This robust profile, including demonstrated immune persistence across various age groups, underscores its potential to provide durable protection.

However, the competitive landscape for meningococcal vaccines is dynamic. While studies indicate MenQuadfi's non-inferiority and even superior geometric mean titers for certain serogroups (C, W, Y) compared to some competitors, one European study noted marginally lower GMTs for serogroup A. This nuance could be relevant in regions where serogroup A remains a significant public health concern. Furthermore, while generally well-tolerated, the safety profile, particularly regarding local and systemic reactions, will continue to be a focus as real-world data accumulates. Sanofi's strategic move positions MenQuadfi to become a cornerstone of infant immunization, but its ultimate success will hinge on demonstrating clear, sustained advantages and securing broad integration into national vaccination programs amidst a competitive market. This approval is a significant step towards reducing the devastating impact of IMD on the youngest and most vulnerable.